Background. Recent clinical trials have shown that switching from PI/r or NNRTI to RPV/TDF/FTC is safe and effective in virologically suppressed HIV-infected patients. In this study, we assessed the tolerability, metabolic profile, maintenance of virologic suppression and changes in renal function after switching to RPV/TDF/FTC in a clinical setting.
Methods. Retrospective chart review of HIV-infected individuals on stable ART for at least 6 months and HIV RNA levels <200 copies/mL whose ART was switched to RPV/TDF/FTC for simplicity, dyslipidemia or ARV intolerance. Wilcoxon signed rank tests and paired t tests were used to test the changes of the lab results and 10-year cardiovascular risk.
Results. 162 out of 175 subjects were analyzed at week 6 ± 4 (n = 140), 24 ± 8 (n = 137) and 48 ± 8 (n = 139). 33% were female; 32% African-American and 57% Hispanic/Latino. Baseline ARV regimen contained NNRTI in 55% and PI/r in 41% of subjects. 18 (11%) of 162 subjects discontinued RPV/TDF/FTC: 3 (2%) due to virologic failure (HIV RNA ≥200 copies/mL) and 6 (4%) grade ≥3 adverse event (2 CNS symptoms, 2 liver toxicity, 1 pancreatitis and 1 acute renal failure). Adverse events occurred in 19 (12%) subjects: 10 reported CNS symptoms, 4 liver toxicity, 2 acute renal failures and 1 each of CV event, pancreatitis and cutaneous reaction. 7 subjects developed virologic failure; 3 subjects continued RPV/TDF/FTC achieving re-suppression.
There was significant improvement (mean ± SD, -0.41 ± 1.54, P = 0.04) in 10-year Framingham Cardiovascular Risk score (%) from baseline (4.57 ± 5.01) to week 24 (4.16 ± 4.71). Mean (SD) changes from baseline in creatinine were 0.03 mg/dL (0.15) at week 24 (P = 0.02). 
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